Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
Roeland Zoutendijk, Jurriën G. P. Reijnders, Ashley Brown, Fabien Zoulim, David Mutimer, Katja Deterding, Jörg Petersen, Wolf Peter Hofmann, Maria Buti, Teresa Santantonio, Florian van Bömmel, Pierre Pradat, Ye Oo, Marc Luetgehetmann, Thomas Berg, Bettina E. Hansen, Heiner Wedemeyer, Harry L. A. Janssen, for the VIRGIL Surveillance Study Group – 11 May 2011 – Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)‐naïve chronic hepatitis B (CHB) patients.